This is the authors' abstract. We don't add key points for this paper.
Proteolysis-targeting chimeras (PROTACs) have emerged as potentially effective therapeutic medicines, but their high molecular weight and poor solubility directly impact their oral bioavailability. This work synthesized
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
He et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: